Premium
Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease
Author(s) -
Brookmeyer Ron,
Abdalla Nada
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.03.005
Subject(s) - dementia , disease , biomarker , medicine , lifetime risk , alzheimer's disease , neurodegeneration , amyloidosis , gerontology , oncology , biology , biochemistry
Lifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten‐year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease. Methods We used a multistate model for the disease process together with US death rates. Results Lifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90‐year old and 29.3% for a 65‐year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%. Discussion Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.